2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

E. Rodriguez

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

Treatment Updates in Early Stage NSCLC - Advances in Thoracic Oncolo…

Total Health

J. Porter

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

John Conibear

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…

Insights from 2023 ASCO® Annual Meeting

J. West

Management of mNSCLC Without Actionable Mutations

Integrity CE

M. Baumgart, S. Liu

ADC in Combination With Immunotherapy for NSCLC

MI&T Congressi

S. Liu

How the Experts Treat: Early Stage NSCLC With Curative Intent

Integrity CE

S. Liu

Progress in the Treatment of NSCLC

Yale Cancer Center

R. Herbst

New Immune Checkpoint Inhibitors in Lung Cancer

MI&T Congressi

S. Peters